Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — Investor Presentation (2026)
45 slides from Scinai Immunotherapeutics's investor presentation, 2026
Slide 1: Advancing I&I Biologics & CDMO Services
CLICK TO EDIT MASTER TITLE STYLE ADVANCING I&I BIOLOGICS & CDMO SERVICES CORPORATE PRESENTATION NON -CONFIDENTIAL 2026 PUBLIC INFORMATION NASDAQ: SCNI
Slide 2: Safe Harbor Statement
Safe CLICKHarbor TO EDIT Statement This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other MASTER TITLE applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding
Slide 3: Scinai is Poised for Near-Term Value Creation
Scinai is CLICK TO EDIT Poised for MASTER TITLE Novel NanoAb Platform providing a proprietary technology and current pipeline of NanoAb -based drugs targeting large markets Significant STYLE First In Class mAb Asset targeting the treatment of underserved orphan skin disorders, creating a de -risked
Slide 4: Team Led by Deep Pharma Experience & Capabilities
Team Led by Deep AMIR REICHMAN – CEO CLICK TO EDIT Senior global pharma leadership positions: Pharmaceutical engineering & supply chain at GSK Vaccines, Belgium; Large projects building vaccine Pharma Experience & manufacturing sites in Belgium, Italy, Germany, Hungary (R&D); Novartis Vaccines (Glob
Slide 5: Advisory Board
Matthias Dobbelstein , Prof. Dr Med. Scientific Director of the Institute of Molecular Oncology at the University CLICK TO EDIT Advisory Board Medical Center Göttingen (UMG), Germany and an Associate Member of the Max Planck Institute for Multidisciplinary Sciences (MPI -NAT). GE MASTER TITLE Distin
Slide 6: Board of Directors with Broad Expertise
Board of Directors with Broad Expertise CLICK TO EDIT MASTER TITLE NORTH AMERICA STYLE Mark Germain, Chairman Aentib Group (Managing Director). Founder, director, chairman, and/or investor in over 20 biotech companies including Alexion, Incyte, Samuel Moed, Director Bristol Myers Squibb (NYSE: BMY)
Slide 7: We are Committed to Executing on a Focused Derisked Strategy
We are Committed CLICK TO EDIT to Executing on a Focu Derisked Strategy MASTER TITLE NanoAb platform provides de -risked STYLE Optionality around mAb product development Two business lines support development path in large markets with strategic financing solutions innovation AND revenue Lead asset
Slide 8: Investment Highlights: How Scinai is Positioned for Success
Investment Highlights: Scinai How is Positioned for Success CLICK TO EDIT MASTER TITLE STYLE Novel NanoAb First In Class Exciting Dual Revenue Collaboration Platform mAb Asset Preclinical Data Streams with Max Planck providing a targeting the setting up the allowing for Society and proprietary treat
Slide 9: What Are NanoAbs?
CLICK TO EDIT MASTER TITLE What Are NanoAbs? STYLE
Slide 10: NanoAbs: Nano Sized, Large Opportunity
NanoAbs: Nano Sized, Large Opportunity CLICK TO EDIT Nanosized antibodies (NanoAbs), also known as VHH -antibodies, are the small antigen -binding fragment / variable domain of heavy antibodies ( HCAbs ) that are part of the immune response of camelids (most famously Alpaca ’s). chain MASTER TITLE T
Slide 11: Tiny Tech, Big Benefits: How NanoAbs Offer Advantage
Tiny Tech, Big Benefits: How NanoAbs Offer Advantage CLICK TO EDIT NanoAbs ’ unique physicochemical attributes can generate multiple crucial advantages vs human monoclonal antibodies ( mAbs ) MASTER TITLE Manufacturing R&D STYLE • 10-times more active pharmaceutical ingredients (API) per gram of man
Slide 12: Pipeline Highlights
Pipeline Highlights -Term Near Milestones in Large Markets CLICK TO EDIT Anti-IL-17 local psoriasis treatment in -vivo proof -of-concept completed, clinical trial in 2027 MASTER TITLE Indication Target Alpacas Immunized VHH Antibody Clones Generated Manufacturing Process & Analytical In vitro / Ex v
Slide 13: Lead Asset Targeting Psoriasis, a Tremendously Underserved Market
Lead Asset Targeting Psoriasis, a Tremendously Unders CLICK TO EDIT MASTER TITLE 15.7 million in the 7 major markets (US, EU 5 and Japan); 80 -90 % with plaque psoriasis STYLE MILD MODERATE SEVERE 50 % 28 % 22 % of patients. of patients. of patients. <3% of the body 3-10% of the body >10% of the bod
Slide 14: Issues with Current Plaque Psoriasis Treatment Landscape
ISSUES with Current Plaque Psoriasis Treatment Landsc CLICK TO EDIT MASTER TITLE Corticosteroid creams, vitamin E+A, vitamin D derivatives Steroids: Skin atrophy; Development of tolerance; Requires daily use. Inconvenient; 10% fill rate of prescriptions STYLE Phototherapy: 20 -35 sessions in an outp
Slide 15: The Problem: An Unmet Need for Localized Treatment
THE PROBLEM: An Unmet LOCALIZED Need Treatment for CLICK TO EDIT MASTER TITLE Even mild patients (~ 50 % of pop.) can suffer considerable burden of disease when they have lesions STYLE in visible or sensitive areas. Some patients have psoriasis in difficult -to-treat areas such as hands, feet, scalp
Slide 16: The Solution: Develop an Anti-IL-17 NanoAb
THE SOLUTION: Develop -IL-17NanoAb an Anti CLICK TO EDIT Strong business and clinical potential for development and commercialization MASTER TITLE STYLE IL-17 is a well -established psoriasis and Bimzelx target and validated by existing therapies, e.g., Cosentyx, Siliq, Taltz There is clinical evide
Slide 17: Benefits of Intralesional Injections of Anti-IL-17A/F VHH
Benefits of Improves Patient Convenience , the injection is designed to be CLICK TO EDIT Intralesional Injections painless and by administering the drug locally once every few months it eliminates the need for twice -daily topical applications, which can have adverse effects and be inconvenient MAST
Slide 18: Our Novel Intradermal Administered Treatment
Our Novel Intradermal Administered Treatment CLICK TO EDIT MASTER TITLE An intradermal Mesotherapy Injection Gun is loaded STYLE with a sterile cartridge containing 1 mL of anti -IL -17 VHH fragment solution. Each mini -injection delivers an aliquot of 30 mL per press of the head button on the pen.
Slide 19: Ex-Vivo Proof of Concept
Ex-Vivo Proof of Concept: Designed to be local, less frequent, safer, and CLICK TO EDIT more affordable NanoAbs Shown to Block MASTER Better ThanTITLE Standard of 150 STYLE Care IL-17 Concentration ( pg /mL) 100 Current standards of Scinai ’s anti -IL -17 NanoAb Impact of ID injected NanoAb in compa
Slide 20: Expression of Markers in Skin Xenografts (In-vivo)
Expression of Markers in Skin Xenografts -vivo):IL-17Isoforms (In CLICK TO EDIT MASTER TITLE Negative Secukinumab Nanoab (once a STYLE IL -17A expression control (red frame) week) Observed in the negative control Blocked by NanoAb and the other therapies At study termination, samples from mice trans
Slide 21: Summary & Next Steps: Anti-IL-17 NanoAb Program
Summary & Next Steps: -IL-17NanoAb AntiProgram CLICK TO EDIT MASTER TITLE Summary Specific Takeaways from In Vivo PoC Study STYLE • Better treatment options for patients with mild to moderate psoriasis and hard -to-treat specific lesions ✓ Mode of action verified: SCN -1 NanoAb blocks IL -17A, F and
Slide 22: First in Class, Fully Human Anti-FasL mAb
CLICK TO EDIT MASTER First TITLE in Class, Fully Human Anti -FasL mAb STYLE
Slide 23: Executive Summary
Executive Summary CLICK TO EDIT A novel, first in class, fully human anti -FasL mAb for the treatment of Pemphigus, SJS/TEN and other underserved skin disorders MASTER TITLE Novel Target Targeting Underserved Populations STYLE • Hu -FasL is a novel target in skin blistering diseases; leveraging a fu
Slide 24: The Target: FasL/Fas Pathway
The Target – FasL/ FasPathway CLICK TO EDIT Fas Ligand (CD95L, CD178) MASTER TITLE PC111 ➢ Type II transmembrane protein, member of TNF family ➢ Expressed on immune cells (activated T cells, NK cells), immune privileged tissues and tumours as membrane-bound FasL (mFasL) STYLE m ➢ Active as homotrime
Slide 25: PC111 Overview: Novel, Non-immunosuppressive, and Selective
PC111 Overview: Novel, -immunosuppressive, Non and Selective CLICK TO EDIT MASTER TITLE Human monoclonal anti -human FasL antibody Optimal solubility, allows reaching high concentrations STYLE [IgG 4, k] (>70mg/ml) Novel, non -immunosuppressive Mode of Action relevant in the pathogenesis of Efficaci
Slide 26: Positive Results in Both PoC Studies in Pemphigus and SJS/TEN
Positive Results in BOTH PoC Studies in Pemphigus and CLICK TO EDIT Pemphigus MASTER TITLE In-vitro ✓ PC 111is effective in preventing FasL - Ex -vivo In-vivo Successfully developed a proprietary in - vivo platform for PC 111testing: the first STYLE dependent acantholysis of normal ✓ (Model 1) It si
Slide 27: The Commercial Opportunity in Rare Skin Diseases
The Commercial Opportunity in Rare Skin Diseases CLICK TO EDIT MASTER TITLE Both indications showcase a greater than $ 1B commercial opportunity and address massive unmet need in the landscape for rare skin disease treatment STYLE Stevens -Johnson Syndrome / Pemphigus 1 Toxic Epidermal Necrolysis 1
Slide 28: The Competitive Landscape is Lacking Options
The Competitive Landscape is Lacking Options.. CLICK TO EDIT Molecule 7 Description Current stage MASTER TITLE Bruton ’s Tyrosine Kinase (BTK) inhibitor PRN 1008 STOPPED for pemphigus Inhibits B cell activation and antibody induction. Fully human antibody against BAFF -R Ianalumab /VAY 736 (B-cell a
Slide 29: PC111 Provides a Groundbreaking Opportunity to Transform Skin Diseases
PC111 Provides a Groundbreaking Opportunity to Transfor CLICK DiseasesTO EDIT MASTER TITLE STYLE Novel, fully human mAb with a unique non -immunosuppressive MoA in skin blistering diseases with Patent and EUR -ODD granted in pemphigus, with additional patent families and/or ODA ’s submitted or Ready
Slide 30: Appendix
CLICK TO EDIT MASTER TITLEAPPENDIX STYLE
Slide 31: Max Planck, UMG, Scinai Collaboration
MAX PLANCK , UMG, The Max Planck CLICK SCINAI TO EDIT COLLABORATION Institute & UMG 1 bring … MASTER TITLE Covering discovery and initial characterization of aimed at predefined list of molecular targets. NanoAbs • World-class science & access to leading scientists • NanoAb platform for the developm
Slide 32: CDMO Services
CLICK TO EDIT MASTER TITLE CDMO SERVICES STYLE
Slide 33: The Market Need for CDMOs
The market need CLICK TO EDIT for CDMOs MASTER TITLE • A contract drug manufacturing organization (CDMO) is a company that provides drug development and manufacturing services to pharmaceutical and biotechnology companies. It offers a diverse range of services, including drug STYLE development, scal
Slide 34: The Market Need and the Offered Services
The market need and the offered services CLICK TO EDIT • The market need to be addressed by this proposal is an Israeli based CDMO service provider offering end -to-end drug development services for biotechnology driven medicinal products relying on bacteria MASTER TITLE or yeast fermentation. • Suc
Slide 35: Biologics CDMO - A Growing Opportunity
Biologics CDMO – CLICK TO EDITa growing opportunity • The Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034 , from US$ 19.8 Billion in MASTER TITLE 2024 , growing at a CAGR of 15.7% during the forecast period from 2025 to 2034 . • The growing demand for biolog
Slide 36: The Competitive Landscape In Israel Is Unique
The CLICK Competitive TO EDIT Landscape In Israel Is Un MASTER TITLE STYLE Specialize in Stem Cells and developing into Local CDMO focused on liquid filling focused on the Human and Mammalian local market. Cells; Stem Cell and Cell Not providing process Therapy applications. development / production
Slide 37: Business Plan Rationale
Business Plan CLICK TO EDIT Rationale • Leveraging our state -of-the-art biologics development and manufacturing facility, we established a Contract Development and Manufacturing Organization (CDMO) in Israel, primarily focused on the burgeoning field of biotech drugs, specifically proteins and MAST
Slide 38: Scinai's Unique Value Proposition as a CDMO
Scinai ’s unique value proposition as a CDMO CLICK TO EDIT ✓ Highly experienced in biotechnological drug production processes, particularly in drug manufacturing process MASTER TITLE development and optimization, scale -up and production for non -clinical and clinical trials. ✓ Management brings man
Slide 39: In-house CDMO De-risks Internal R&D Investments
In-house CDMO -risks DeInternal R&D Investments CLICK TO EDIT MASTER TITLE STYLE ASEPTIC GMP MANUFACTURING SUITES STATE -OF -THE - ART R &D AND QC LABORATORIES PHARMA CMC EXPERIENCE 39
Slide 40: CDMO Strategic Guiding Principles
CDMO CLICK TO Strategic EDIT Guiding Principles MASTER TITLE SCINAI ’S CDMO STYLE VALUE PROPOSITION: Target Markets: Israel, Europe, USA Experienced and professional team Growing CDMO available to execute business unit drug development Early -stage biopharma drug buffers R&D risk by projects at high
Slide 41: GMP Manufacturing and R&D Labs
GMP CLICKManufacturing TO EDIT and R&D Labs MASTER TITLE Industry standard aseptic facility: Labs, cleanroom, warehouses, offices STYLE Analytical methods development combined with best -in-class QC capabilities and Labs for manufacturing process development and scale -up allow for the implementatio
Slide 42: Industry Standard Aseptic Facility
Industry Standard CLICK TO EDIT Aseptic Facility MASTER TITLE • cGMP manufacturing designed to meet FDA and EMA regulatory standards • ASTM E 2500 Standard STYLE • 21 CFR Part 11& GAMP 5 • Previously cGMP approved by the Israeli Ministry of Health (MOH) & EU QP • Labs for manufacturing process devel
Slide 43: GMP Production
GMP Production CLICK TO EDIT Decades of accumulated experience in manufacturing process development, analytical method MASTER TITLE development, and quality control under GLP conditions coupled with robust QMS • Scinai ’s state -of-the-art cGMP facility is cGMP process equipment includes : STYLE des
Slide 44: Process Development - Up & Scale
Process Development CLICK TO EDIT -Up& Scale Process development, scale -up and optimization under design of experiments (DOE) methodology incorporating Quality by MASTER TITLE Design principles, with high end manufacturing equipment UPSTREAM STYLE Ambr ® 250 system with four individual fermentor mo
Slide 45: Analytical Methods Development
Analytical Methods CLICK TO EDIT Development • Scinai CDMO ’s experienced team of scientists and state -of-the-art facilities ensure accuracy and reliability of MASTER TITLE analytical characterization, quality control and quality assurance services. • Our boutique service includes custom packages f
Scinai Immunotherapeutics — Investor Presentation (2026) on 6ix